Drug & intervention

fluorouracil

RxCUI 4492

Clinical trials85
Recruiting5
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Fluorouracil

Fluorouracil (5-FU, 5-fluorouracil), sold under the brand name Adrucil among others, is a cytotoxic chemotherapy medication used to treat cancer. By intravenous injection it is used for treatment of colorectal cancer, oesophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. As a cream it is used for actinic keratosis, basal cell carcinoma, and skin warts. Side effects of use by injection are common. They may include inflammation of the mouth, loss of appetite, low blood cell counts, hair loss, and inflammation of the skin. When used as a cream, irritation at the site of application usually occurs. Use of either form in pregnancy may harm the fetus. Fluorouracil is in the antimetabolite and pyrimidine analog families of medications. How it works is not entirely clear, but it is believed to involve blocking the action of thymidylate synthase and thus stopping the production of DNA. Fluorouracil was patented in 1956 and came into medical use in 1962. It is on the World Health Organization's List of Essential Medicines. In 2023, it was the 267th most commonly prescribed medication in the United States, with more than 900,000 prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · 2025-12-23
RECRUITING
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsNCT07277270 · 2025-12-03
RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialNCT05564377 · 2023-04-07
RECRUITING
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsNCT05733000 · 2023-03-08
RECRUITING
AB122 Platform StudyNCT04999761 · 2021-06-01
RECRUITING
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsNCT06544655 · 2024-10-10
ACTIVE_NOT_RECRUITING
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171 · 2023-10-13
ACTIVE_NOT_RECRUITING
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerNCT04929028 · 2022-08-09
ACTIVE_NOT_RECRUITING
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701 · 2022-07-05
ACTIVE_NOT_RECRUITING
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Breast Cancer Treatment Based on Organ-like CultureNCT03925233 · 2019-01-02
UNKNOWN
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaNCT03837977 · 2018-11-13
COMPLETED
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant ChemotherapyNCT03349177 · 2017-11-27
UNKNOWN
PEN-866 in Patients With Advanced Solid MalignanciesNCT03221400 · 2017-08-29
UNKNOWN
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable CancerNCT03009058 · 2017-05-31
TERMINATED
Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast CancerNCT02897050 · 2016-09-01
SUSPENDED
A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast CancerNCT02742051 · 2016-06-01
COMPLETED
Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin LesionsNCT02059499 · 2015-12-28
COMPLETED
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26
TERMINATED
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade LesionsNCT02135419 · 2014-09-24
COMPLETED
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced CancerNCT02124148 · 2014-06-18
COMPLETED
Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast CancerNCT02115152 · 2014-06-01
UNKNOWN
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor CellsNCT01779050 · 2013-12-19
TERMINATED
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic CancerNCT01959672 · 2013-09-06
COMPLETED
Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast CancerNCT01880385 · 2011-03-01
UNKNOWN
Molecular Triaging of Newly Diagnosed Breast CancerNCT01159236 · 2010-09-01
WITHDRAWN
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast CancerNCT01093235 · 2009-04-01
UNKNOWN
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by SurgeryNCT00936832 · 2009-04-01
WITHDRAWN
Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer PatientsNCT00820547 · 2009-01-01
COMPLETED
Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By SurgeryNCT00963729 · 2008-09-01
COMPLETED
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast CancerNCT00629278 · 2007-12-01
UNKNOWN
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic CancerNCT01068327 · 2007-11-05
COMPLETED
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or LungNCT00557102 · 2007-09-01
COMPLETED
Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerNCT00630032 · 2007-09-01
COMPLETED
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by SurgeryNCT00513266 · 2007-06-01
UNKNOWN
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast CancerNCT00872625 · 2007-04-01
COMPLETED
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast CancerNCT00533936 · 2006-09-01
UNKNOWN
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal CancerNCT00324415 · 2006-09-01
COMPLETED
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast CancerNCT00429299 · 2006-08-01
COMPLETED
Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By SurgeryNCT00301925 · 2005-12-16
UNKNOWN

Leading sponsors

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.